Professor David Nutt has spent a career making the argument for a rational, evidence-based approach to drug policy and drug use. The scientific evidence still challenges perceived wisdom on drugs and for that reason can appear to be contentious. In this podcast, the Professor explores the actual harms and potential benefits of various drugs, challenging myths surrounding classification and legislation, and exploring the societal impact of poorly informed drug policy. Using evidence in public policy should not be controversial. A podcast for anyone interested in understanding the scientific truth about drugs, free from political or moral concern.
https://drugscience.org.uk/
episode 68: 68. Bipolar, Schizophrenia and Depression with Prof Allan Young
Professor Allan Young is a psychopharmacologist and the Director of the Centre for Affective Disorders in the Department of Psychological Medicine in the Institute of Psychiatry, Psychology and Neuroscience at King’s College London. Prof Young is the clinical academic lead in the Psychological Medicine and Integrated Care Clinical Academic Group in the South London and Maudsley NHS Trust where he is also a Consultant Psychiatrist and the head of the National Affective Disorders Tertiary Clinic.
Professor Young’s research interests focus on the cause and treatments for severe psychiatric illnesses, particularly mood disorders like depression. He has received research grant funding from the UK Medical Research Council, the Wellcome Trust, and numerous other respected funding agencies worldwide. He has published over 400 peer-reviewed publications and a number of books about psychopharmacology and affective disorders. According to the 2014 Thomson Reuters Highly Cited Researcher list, Professor Young was recently ranked as one of the world's leading scientific minds in the field of Psychiatry and Psychology.
Depression
Bipolar disorder
Major depressive episode
Anhedonia
ICD-10
DSM-5
Atypical depression
Immuno-metabolic depression
SSRI
Rapid cycling bipolar disorder
Tricyclic antidepressants
Monoamine oxidase inhibitors (MAOIs)
Dopamine receptor D2
Cognitive Remediation Therapy
Institute of Psychiatry, Psychology & Neuroscience
CBT
Ketamine
Esketamine: Ketamine nasal spray
Bioavailability
Psilocybin: From Serendipity to Credibility?
COMPASS Pathways
★ Support this podcast ★